Start the program by clicking on the Start Program icon at the bottom of this page.
|
| Program Title |
 |
|
Impact of Extent of Resection on Survival in Glioblastoma
Release Date: December-15-09
Credit Expiration Date: December-15-10
|
|
|
 |
| Program Developer/Facilitator |
 |
|
Medical Communications Media, Inc. |
|
|
|
| Target Audience |
|
|
| This educational activity is designed to meet the needs of neurosurgeons, neuro-oncologists, radiation oncologists, medical oncologists, and other healthcare providers interested in the treatment of primary gliomas. |
|
|
|
| Credit Hours |
|
|
|
|
|
| Medium |
|
|
|
|
|
| Program Description |
|
|
| Primary malignant brain tumors remain one of the most challenging human tumors to treat. The infiltrative nature of these lesions present even at the time of initial diagnosis intellectually defies the concept of a complete resection. Nonetheless, the role of surgical intervention has evolved as techniques progress and clinical studies have attempted to examine the contribution of surgical procedures to survival in patients with malignant glioma. The decision to proceed with surgical resection versus biopsy or subtotal resection remains an area of active debate. |
|
|
|
| Learning Objectives |
|
|
|
|
|
| Faculty |
|
|
Timothy Ryken, MD MS FACS
Department of Neurosurgery
Iowa Spine and Brain Institute
Waterloo, Iowa
|
|
|
|
| Disclosures |
|
|
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Dr. Ryken discloses product consultation to Medtronic; speakers’ bureau participation for Schering-Plough and Eisai; and research funding from Medtronic and Eisai. |
|
|
|
| Commercial Support Statements |
|
|
This activity is supported by an educational grant from Schering-Plough Corporation. |
|
|
|
|
|
| Credit Statements |
|
|
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media, Incorporated. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians. |
|
|
AKH Inc. designates this educational activity for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. |
|
|
|
|
|
| Instructions |
|
|
|
|
|
| Certificate Fee |
|
|
|
|
|
| Disclaimer |
|
|
| © 2009. All rights reserved. None of the contents of this publication may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this publication are those of the faculty members and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, AKH Inc., or Schering-Plough. Any medications, diagnostic procedures, or treatments discussed by the faculty members should not be used by clinicians or other healthcare professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities. |
|
|
| |
